Literature DB >> 30055250

Covered stenting and transcatheter embolization of splenic artery aneurysms in diabetic patients: A review of endovascular treatment of visceral artery aneurysms in the current era.

Massimo Venturini1, Paolo Marra2, Anna Colarieti2, Giulia Agostini2, Carolina Lanza2, Luigi Augello2, Simone Gusmini2, Marco Salvioni2, Germano Melissano3, Paolo Fiorina4, Roberto Chiesa3, Francesco De Cobelli5, Alessandro Del Maschio5.   

Abstract

Diabetes mellitus is associated with both microvascular and macrovascular complications, which can result in visceral aneurysms as for example splenic artery aneurysms: in their management, an endovascular treatment, less invasive than surgery, is generally preferred. Endovascular treatment of splenic artery aneurysms can be based either on covered stenting (CS) or transcatheter embolization (TE). CS generally allows aneurysm exclusion with vessel preservation, while TE usually determines target artery occlusion with potential risk of distal ischemia. We performed a review of the existing literature on endovascular treatment of visceral artery aneurysms (VAAs) and psudoaneurysms (VAPAs) in the current era.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Covered stent; Diabetes; Endovascular treatment; Transcatheter embolization; Visceral aneurysm

Mesh:

Year:  2018        PMID: 30055250     DOI: 10.1016/j.phrs.2018.07.023

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  2 in total

Review 1.  Splenic Artery Pseudoaneurysms: The Role of ce-CT for Diagnosis and Treatment Planning.

Authors:  Fabio Corvino; Francesco Giurazza; Anna Maria Ierardi; Pierleone Lucatelli; Antonello Basile; Antonio Corvino; Raffaella Niola
Journal:  Diagnostics (Basel)       Date:  2022-04-17

2.  Single-Center Experience With Endovascular Treatment for Splenic Artery Aneurysms in Long-Term Follow-Up: A Retrospective Study.

Authors:  Yanyan Cao; Songlin Song; Tao Ouyang; Chuansheng Zheng
Journal:  Front Cardiovasc Med       Date:  2022-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.